Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma

Elisa Franceschi; Nora Drick; Jan Fuge; Tobias Welte; Hendrik Suhling

doi:10.1183/23120541.00138-2022

Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma

ERJ Open Res. 2022 Sep 26;8(3):00138-2022. doi: 10.1183/23120541.00138-2022. eCollection 2022 Jul.

Authors

Elisa Franceschi¹, Nora Drick², Jan Fuge^{2

3}, Tobias Welte^{2

3}, Hendrik Suhling²

Affiliations

¹ Dept of Respiratory Diseases, Ospedale Luigi Sacco, Polo Universitario, ASST Fatebenefratelli-Sacco and Dept of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Milan, Italy.
² Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
³ Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL).

Abstract

This study of the eosinophil cationic protein (ECP) as predictor of clinical response to biological therapy in severe asthma found that ECP is not useful in unselected patients but may have a role in those not exposed to oral corticosteroids. https://bit.ly/398RwEk.